Un audited Financials Results for the quarter and half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals reported weak Q2 FY26 results with revenue from operations of Rs 146.25 lakhs, slightly down from Rs 151.88 lakhs in the year-ago quarter. Total income fell sharply to Rs 165.49 lakhs vs Rs 250.17 lakhs, a decline of about 34% year-on-year. The company swung to a net loss of Rs 258.85 lakhs for the quarter, compared to a loss of Rs 97.37 lakhs last year. Loss before tax widened to Rs 362.21 lakhs (vs Rs 125.20 lakhs), largely because the company booked an Expected Credit Loss (ECL) provision of Rs 205.43 lakhs against long-pending trade receivables during the quarter. On the financing side, the company issued 10,249,998 convertible share warrants and received Rs 307.50 lakhs (25% upfront) as part-subscription. The auditor (A.M. Reddy & D.R. Reddy) issued an unqualified limited review report with no qualifications or emphasis-of-matter remarks.
The widening losses, sharp drop in total income, large ECL provision on receivables, and negative operating cash flow (Rs -367.89 lakhs for the half year) paint a weak picture that is likely to weigh negatively on the stock. The share warrant issue may dilute existing shareholders once converted, which adds to near-term overhang.